MAIA Biotechnology, Inc.
News
(3)April 2026
MAIA Biotechnology Highlights THIO Phase 2 Progress in Annual Report
# 🧾 What This Document Is This is the **Annual Report to Shareholders (ARS)** for MAIA Biotechnology, Inc. Think of it as a company's "year-in-review" magazine, designed for investors. It’s different from the more technical 10-K filing—it’s shorter, more visual, and focuses on telling the company'
MAIA Biotechnology, Inc. — DEF 14A Filing
# 🧾 What This Document Is — A Roadmap for the Annual Vote This is a **Definitive Proxy Statement (DEF 14A)**. Think of it as the official rulebook and information packet for MAIA Biotechnology's upcoming annual shareholder meeting. The company is required to send this to shareholders so they can m
March 2026
MAIA Biotechnology, Inc. — 8-K Filing
# 🧾 What This Document Is This is a **press release** (filed as an Exhibit to an 8-K) from MAIA Biotechnology. The company is sharing exciting early results from a clinical trial of its cancer drug. They presented this data at a major medical conference in Copenhagen on March 27, 2026. 👉 **Why it
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.